Funding Opportunity RFA-HG-17-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to participate in the Implementing Genomics in Practice (IGNITE) II: Pragmatic Clinical Trials Network. This network will conduct pragmatic clinical trials to measure the clinical utility and cost-effectiveness of genomic medicine interventions; assess approaches for real-world application of genomic medicine in diverse clinical settings; and produce generalizable knowledge on the types of genomic medicine interventions requiring randomized clinical trials and effective methods for conducting them. IGNITE II will include multiple clinical groups including enhanced diversity clinical groups, and a single Coordinating Center (CC). This FOA invites applications for the Coordinating Center (CC) and runs in parallel with companion FOAs that invite applications for the CGs (RFA-HG-17-008) and the enhanced diversity CGs (RFA-HG-17-009).

Funding Opportunity RFA-HD-18-008 from the NIH Guide for Grants and Contracts. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), through the Fertility and Infertility (FI) Branch, provides funding for a limited number of research centers in the reproductive sciences. These centers provide an arena for multidisciplinary interactions among basic and clinical scientists interested in establishing high quality translational research programs in this scientific area. The centers also serve as national resources for the training and career development of junior scientists electing to pursue biomedical research careers in reproduction and infertility. Finally, center investigators develop and participate in community outreach and education efforts to increase awareness and convey the importance and implications of their research activities to the general public. The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive health through research excellence and innovation.

Notice NOT-NS-17-025 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HD-18-013 from the NIH Guide for Grants and Contracts. The goal of this funding opportunity announcement (FOA) is to advance the field of population dynamics research by increasing research impact, innovation, and productivity; developing junior scientists; and maximizing the efficiency of research support.

Notice NOT-OD-17-094 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-334 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early stage investigators in Synthetic Biology are especially encouraged to apply.

Notice NOT-HS-17-018 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-095 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-096 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-039 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-335 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in: 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NIA, and/or NIDCD; and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes. The main emphasis of projects submitted under this FOA should be in the discovery of cell-based chemical probes. Applicants interested in developing in vivo chemical probes may wish to apply using the companion R01 mechanism (PAR-17-336).

Funding Opportunity PAR-17-336 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in understanding biological processes relevant to the missions of NIMH, NEI, NIAAA, NIDA, NIA and/or NIDCD and 2) discovery and/or validation of novel, biological targets that will inform studies of brain disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease-related biological targets and biological processes.

Funding Opportunity PAR-17-333 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) will support innovative exploratory/developmental investigations on primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. In addition, this FOA aims to encourage analyses of clinical data and samples maintained in primary immunodeficiency registries, consortium databases and repositories to address questions relevant to primary immunodeficiency research.

Notice NOT-AA-17-008 from the NIH Guide for Grants and Contracts

Notice NOT-RM-17-035 from the NIH Guide for Grants and Contracts

Notice NOT-AR-17-018 from the NIH Guide for Grants and Contracts

Notice NOT-AG-17-012 from the NIH Guide for Grants and Contracts

Notice NOT-AG-17-013 from the NIH Guide for Grants and Contracts

Notice NOT-TW-17-006 from the NIH Guide for Grants and Contracts

Notice NOT-TW-17-007 from the NIH Guide for Grants and Contracts